Warren Buffett and Stephen Curry Charity Dinner Auction Raises $27 Million for Nonprofits 
Samsung, Union Edge Closer to Deal as Strike Threat Looms 
Sonova Beats Profit Forecasts Despite Cochlear Implant Weakness 
Standard Chartered Targets Higher Profitability With Major Workforce Cuts 
OpenAI Wins Elon Musk Lawsuit as Jury Rejects Claims Over AI Mission 
FTC Antitrust Probe Targets Arm Holdings Over Chip Licensing Practices 
US-China Trade Talks Sideline Chip Export Controls as Nvidia China Sales Draw Attention 
Applied Materials Forecasts Strong Q3 Revenue as AI Chip Demand Accelerates 
Anthropic to Brief Financial Stability Board on AI-Driven Cyber Risks 
Thyssenkrupp to Shut Down Indiana Automotive Plant by March 2026 
YouTube and Snap Settle School District Mental Health Lawsuit Ahead of Major Social Media Trial 
TSMC Stake Sale Sends Vanguard Semiconductor Shares Lower 
Standard Chartered Appoints Manus Costello as New CFO Amid Leadership Reshuffle 
DOJ May Drop Gautam Adani Fraud Charges Amid $10 Billion U.S. Investment Plan 
Honda Shares Jump as Automaker Forecasts Profit Recovery Despite Historic Loss 
Elliott Targets Bio-Rad as Shares Continue to Struggle 
SOUTH SAN FRANCISCO, Calif., Sept. 20, 2016 -- Mateon Therapeutics, Inc. (Nasdaq:MATN), a clinical-stage biopharmaceutical company developing vascular disrupting agents for the treatment of orphan oncology indications, today announced it will present an overview of the company at the Ladenburg Thalmann 2016 Healthcare Conference on Tuesday, September 27, 2016 at 4:00 p.m. eastern time at the Sofitel New York.
To listen to a live webcast of the presentation, please visit the Company's website, www.mateon.com. Under the "Investors & News" tab, select the link to "Events & Presentations." A replay of the webcast will be available at this same location for a period of time following the conclusion of the live event.
About Mateon
Mateon Therapeutics, Inc. is a biopharmaceutical company seeking to realize the full potential of vascular targeted therapy (VTT) in oncology. VTT includes vascular disrupting agents (VDAs) such as the investigational drugs that Mateon is developing, and anti-angiogenic agents (AAs), a number of which are FDA-approved and widely used in cancer treatment. These two approaches have distinct yet complementary mechanisms of action.
At Mateon, we believe that we can significantly improve cancer therapy by employing these two complementary approaches simultaneously. When utilized this way, VDAs obstruct existing blood vessels in the tumor leading to significant central tumor cell death while AAs prevent the formation of new tumor blood vessels.
Mateon is committed to leveraging our intellectual property and the product development expertise of our highly skilled management team to enable VTT to realize its true potential and to bring much-needed new therapies to cancer patients worldwide.
CONTACT for investors and media: [email protected] 650-635-7000
